Hidradenitis Suppurativa Market

The global Hidradenitis Suppurativa Market is valued at USD 894.3 Million in 2024 and is projected to reach a value of USD 1315.3 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 4.9% between 2025 and 2035.

The Hidradenitis Suppurativa market industry is anticipated to grow rapidly during the forecast period. Hidradenitis suppurativa, often known as acne inversa, is a chronic dermatological condition characterized by swollen lumps. Hormonal imbalances, friction from clothing, and sweating cause hidradenitis suppurativa.

Increased funding for healthcare infrastructure, rising activities by public and commercial organizations to raise awareness, rising rates of obesity, and an increase in the frequency of skin diseases are all contributing factors, are the key market drivers enhancing the Hidradenitis Suppurativa market growth.

Key Highlights

• In 2024, based on the Treatment type, the Medication category accounted for significant market share of 62.30% in Hidradenitis Suppurativa market industry
• In 2024, based on the Route of administration, the topical category accounted for significant market share of 69.90% in Hidradenitis Suppurativa market
• In 2024, based on the End Users, the Hospital pharmacies category accounted for significant market share of 66.70% in Hidradenitis Suppurativa market
• North America dominated the Hidradenitis Suppurativa market industry with largest market share of 46.50% in 2024
• Europe region is anticipated to grow at the highest CAGR during the forecast period

Treatment Type Overview

The Treatment type segment is divided into Medication and Surgery. Medication segment is categorized into Biologics, Antibiotics, Hormonal Therapy, Immune Suppurativa Drugs, Zinc Supplements, and Pain Medication. The Medication segment held the largest share of 62.30% in the Hidradenitis Suppurativa market industry.

The medication segment in the Hidradenitis Suppurativa market is driven by several key factors such as rising global prevalence of HS, alongside increasing awareness and earlier diagnoses, has significantly expanded the demand for effective treatment options. The development of targeted treatments, including immune modulators and biologics, has further fueled the market by offering more personalized and effective therapies. Additionally, the increasing focus on symptom management, particularly pain relief through NSAIDs and opioids, is driving the demand for supportive pain medications

• Biologics: The Biologics segment is driven by several factors, primarily the effectiveness of biologics in treating moderate to severe cases of the condition. Biologic therapies are among the most advanced treatments for hidradenitis suppurativa. These medications, such as adalimumab (Humira) and infliximab (Remicade), target specific immune system molecules involved in inflammation. Biologics help to reduce the inflammation that leads to painful abscesses and tunnels under the skin, improving skin healing and reducing flare-ups in moderate to severe cases of HS
• Antibiotics: The Antibiotics segment is driven by managing bacterial infections and preventing flare-ups associated with the disease. Antibiotics, including clindamycin and tetracyclines, are commonly used to manage infections and reduce the bacterial growth associated with hidradenitis suppurativa lesions. They are particularly effective in early stages of the disease or in cases with secondary bacterial infections, helping to manage the symptoms and prevent further complications
• Hormonal Therapy: The Hormonal therapy segment is driven by its ability to regulate the hormonal imbalances that contribute to the disease's progression. Hormonal therapy, such as the use of oral contraceptives or anti-androgens like spironolactone, is often used for managing HS, especially in women. Hormonal fluctuations are known to contribute to the disease, and by regulating hormones, these therapies can reduce the frequency of flare-ups. They are commonly used for patients whose symptoms worsen around menstruation or in those with hormonal imbalances
• Immune Suppressive Drugs: The immune suppressive drugs segment in Hidradenitis Suppurativa industry is driven by the increasing recognition of the autoimmune and inflammatory nature of the disease. Immune suppressive drugs, like methotrexate or cyclosporine, are used in cases of severe HS that do not respond to other treatments. These drugs work by suppressing the immune system's overactive response, reducing inflammation and the formation of abscesses and tunnels under the skin. They are often used in combination with other therapies
• Zinc Supplements: The Zinc supplements segment is driven by growing evidence supporting the role of zinc in managing the condition. Zinc is an essential mineral that plays a role in immune function and wound healing. Some studies have shown that zinc supplementation can help reduce the severity of hidradenitis suppurativa, especially in patients with zinc deficiency. It is often used as an adjunctive therapy to support overall treatment regimens
• Pain Medication: Pain medication is crucial in Hidradenitis Suppurativa market due to the chronic pain and discomfort associated with abscesses, cysts, and skin lesions. Over-the-counter pain medications, such as NSAIDs (non-steroidal anti-inflammatory drugs) or opioids in severe cases, may be prescribed to manage pain and inflammation. Pain management also plays a supportive role in improving quality of life for HS patients

Route of Administration Overview

The Route of Administration segment is divided into oral and tropical. The topical segment held the largest share of 69.90% in the Hidradenitis Suppurativa market industry.

• Topical: The topical segment in the Hidradenitis Suppurativa market is driven by the growing preference for localized treatments that offer targeted relief with minimal systemic side effects. The increasing recognition of the importance of early intervention and the desire for non-invasive treatment options drive the demand for topical treatments, especially for patients in the initial stages of the disease. Additionally, the growing focus on personalized medicine and the development of targeted topical treatments designed to address the specific pathophysiology of HS further support the segment's growth
• Oral: Oral medications, such as antibiotics, hormonal therapies, immune suppressants, and pain relievers, are often preferred by patients due to their ease of administration and ability to manage symptoms without the need for frequent medical visits or injections. The segment is driven by the increasing prevalence of the condition and the demand for convenient, effective treatment options. Additionally, immune-suppressive drugs and pain management medications, often in oral form, are essential for severe cases, providing relief from the intense pain and inflammation caused by the condition

End User Overview

The End User segment is divided into hospital pharmacies, retail pharmacy, and online pharmacy. The hospital pharmacies segment held the largest share of 66.70% in the Hidradenitis Suppurativa market industry.

An increasing number of initiatives from governmental bodies in enhancing the infrastructure of hospitals pharmacies are expected to boost the growth of the Hidradenitis Suppurativa market. The segment is driven by several factors including the increasing demand for specialized care and the availability of advanced treatment options in hospital settings. Hospitals often provide comprehensive healthcare services, including the use of biologics and immunosuppressive therapies, which require careful management and monitoring, making them a critical component of HS treatment.

Regional Overview

In 2024, the Hidradenitis Suppurativa market size of the North America is USD 415.8 Million.

North America Hidradenitis Suppurativa market industry is driven by a high prevalence of the condition, increased awareness, and advancements in treatment options. The region's well-developed healthcare infrastructure and access to cutting-edge treatments, including biologics and immune-modulating therapies, are critical factors driving Hidradenitis Suppurativa market growth. North America also benefits from an active research environment, with numerous clinical trials focused on novel therapies and improving treatment outcomes for HS patients. Furthermore, increased patient awareness, alongside support from patient advocacy groups, is leading to more people seeking early diagnosis and treatment.

U.S. Hidradenitis Suppurativa Market Analysis

The U.S. Hidradenitis Suppurativa market is driven by high prevalence of the condition and an advanced healthcare system. The U.S. also leads in the adoption of novel therapies, with major pharmaceutical companies focusing on the development and commercialization of new drugs specifically targeting hidradenitis suppurativa. For instance, in March 2023, A novel monoclonal antibody could be a promising treatment for hidradenitis suppurativa as phase 2 clinical trial results showed an improvement in total abscess and nodule count after 16 weeks of treatment. Additionally, the rising awareness of the condition, coupled with increasing research and clinical trials, has contributed to improved diagnosis and better treatment outcomes.

Europe Hidradenitis Suppurativa Market Analysis

The Europe Hidradenitis Suppurativa market size is expected to account for a substantial share driven by factors such due to their advanced healthcare systems, high awareness of chronic dermatological conditions, and strong focus on research and treatment development. the European Hidradenitis Suppurativa market industries is supported by a combination of advanced medical expertise, government healthcare initiatives, and growing patient awareness, propelling the adoption of new treatments and improving patient outcomes.

Hidradenitis Suppurativa Market Industry Trends

1. Increased Adoption of Biologics: Rising use of biologics like adalimumab for severe HS cases due to their efficacy in reducing flare-ups and promoting skin healing
2. Advancement in Treatment Options: Introduction of new therapies such as targeted biologics and oral medications for better disease management
3. Rising Patient Awareness: Increasing awareness about HS symptoms, early diagnosis, and the importance of specialized care
4. Growing Research and Clinical Trials: Ongoing clinical trials exploring new drug candidates and therapeutic approaches, expanding treatment options
5. Shift Toward Multidisciplinary Care: Collaboration between dermatologists, immunologists, and surgeons to provide comprehensive care

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Rise in the prevalence of skin diseases

The rise in the prevalence of skin diseases, including conditions like hidradenitis suppurativa (HS), is significantly driving the Hidradenitis Suppurativa market. Hidradenitis suppurativa is a chronic, inflammatory skin disorder characterized by painful abscesses, tunnels under the skin, and scarring, primarily affecting areas with sweat glands such as the armpits, groin, and under the breasts. The increasing incidence of hidradenitis suppurativa is linked to factors such as genetic predisposition, obesity, smoking, and hormonal changes. Globally, growing prevalence is contributing to heightened demand for effective treatments and driving Hidradenitis Suppurativa market industry.

Increasing investment for healthcare infrastructure

As governments and private sectors around the world continue to prioritize healthcare development, there is a growing emphasis on expanding access to specialized care, improving diagnostic capabilities, and enhancing treatment options for chronic conditions like hidradenitis suppurativa. Rising initiatives by public and private organizations to spread awareness and increasing number of cases of obesity will expand the Hidradenitis Suppurativa market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of market. Moreover, rising geriatric population and rising incidences of smoking will enhance the growth rate of the market.

Competitive Landscape

The Hidradenitis Suppurativa market report is characterized by the presence of both established players and emerging companies, each strive for market share through product innovation, strategic partnerships, and geographic expansion. Industry giants like InfraRx N.V., Novartis AG, UCB Biopharma SPRL, AbbVie Inc, Eli Lily and Company, Aristea Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Priovant Therapeutics, Amgen Inc, Aclaris Therapeutics Inc, Boehringer Ingelheim. Additionally, Strategic partnerships between large pharmaceutical companies and smaller research-driven firms are becoming common to expedite drug development and commercialization. Research and development remain a critical focus, as the market demands more effective treatments for moderate to severe cases.

The key players in the global Hidradenitis Suppurativa market industry report include - InfraRx N.V., Novartis AG, UCB Biopharma SPRL, AbbVie Inc, Eli Lily and Company, Aristea Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Priovant Therapeutics, Amgen Inc, Aclaris Therapeutics Inc, Boehringer Ingelheim among others.

Recent Market Developments

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

• In June 2022, Roivant Sciences and Pfizer announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant was established in September 2024 through a transaction between Roivant and Pfizer, in which Pfizer licensed oral and topical brepocitinib’s global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25% equity ownership interest in Priovant

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

• In May 2022, MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that the first patient has been randomized and dosed, in a U.S. site, in its global Phase 2 clinical trial evaluating sonelokimab, an investigational Nanobody® designed to treat inflammatory disease, in patients with moderate-to-severe hidradenitis suppurativa (HS)

The global Hidradenitis Suppurativa market can be categorized as Clinical stages, Treatment type, Route of Administration, End User, and Region.